The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of an educational program for patients with pancreatic and biliary cancers, and their caregivers.
 
Reiko Makihara Ando
Honoraria - Lilly; MSD; Nippon Boehringer Ingelheim; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical
 
Chikako Doutani
No Relationships to Disclose
 
Sayaka Kanehira
No Relationships to Disclose
 
Mariko Nishizawa
No Relationships to Disclose
 
Kyoko Hirata
No Relationships to Disclose
 
Hitomi Miura
No Relationships to Disclose
 
Moe Nishio
No Relationships to Disclose
 
Tomoko Suzuki
No Relationships to Disclose
 
Yumiko Fujimaki
No Relationships to Disclose
 
Naoko Goto
No Relationships to Disclose
 
Rieko Shimizu
No Relationships to Disclose
 
Hironobu Inoguchi
No Relationships to Disclose
 
Satoshi Shiba
No Relationships to Disclose
 
Yasunari Sakamoto
No Relationships to Disclose
 
Shunsuke Kondo
Research Funding - AstraZeneca (Inst); Lilly (Inst); Pfizer (Inst)
 
Chigusa Morizane
Honoraria - Fujifilm; Lilly; Nobelpharma; Novartis; Pfizer; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Novartis; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Eisai (Inst); GlaxoSmithKline (Inst); Nobelpharma (Inst); ONO PHARMACEUTICAL (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Hideki Ueno
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Baxalta; Lilly; NanoCarrier; Taiho Pharmaceutical; Yakult Honsha
 
Ken Shimizu
No Relationships to Disclose
 
Takuji Okusaka
Honoraria - AstraZeneca Japan; Baxter; Bayer Yakuhin; Celgene; Chugai Pharma; Dainippon Sumitomo Pharma; EA Pharma; Fujifilm; Lilly; Merck Serono; Nippon Chemiphar; Nippon Kayaku; Nobelpharma; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo; Dainippon Sumitomo Pharma; Lilly; Nippon Boehringer Ingelheim; Taiho Pharmaceutical; Zeria Pharmaceutical
Research Funding - AstraZeneca Japan; Baxter; Baxter; Bayer Yakuhin; Chugai Pharma; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; GlaxoSmithKline K.K.; GlaxoSmithKline K.K.; Kowa; Kyowa Hakko Kirin; Lilly; Merck Serono; NanoCarrier; NanoCarrier; Nippon Boehringer Ingelheim; Nobelpharma; Nobelpharma; Novartis; Ono Pharmaceutical; Pfizer; Shizuoka Industry; Shizuoka Industry; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical; Zeria Pharmaceutical